Kura Oncology (NASDAQ: KURA) CEO exercises options, increases share stake

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Kura Oncology, Inc. President and CEO Troy Edward Wilson exercised stock options to acquire 6,103 shares of common stock at $6.15 per share on March 23, 2026. These options were fully vested and, after the exercise, that option grant was fully used.

Following the transaction, he directly holds 435,456 shares of Kura Oncology common stock. The filing also shows indirect holdings of 279,194 shares held by One Fish Two Fish Revocable Trust and 300,000 shares held by Lorax Charitable Remainder Unitrust, reflecting additional ownership through related entities.

Insider Trade Summary

6,103 shares exercised/converted

Mixed 4 txns

Insider WILSON TROY EDWARD

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	6,103	$0.00	--
Exercise	Common Stock	6,103	$6.15	$38K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 435,456 shares (Direct); Common Stock — 279,194 shares (Indirect, by One Fish Two Fish Revocable Trust)

Footnotes (1)

Represents stock options exercised. This option is fully vested.

Form 4 Insider Transactions: What Each Field Means →

03/25/2026 - 09:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON TROY EDWARD

(Last)

(First)

(Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO

CALIFORNIA

92121

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/23/2026		M⁽¹⁾		6,103	A	$6.15	435,456	D
Common Stock								279,194	I	by One Fish Two Fish Revocable Trust
Common Stock								300,000	I	by Lorax Charitable Remainder Unitrust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$6.15	03/23/2026		M⁽¹⁾		6,103		⁽²⁾	01/22/2027	Common Stock	6,103	$0	0	D

Explanation of Responses:

1. Represents stock options exercised.

2. This option is fully vested.

	Teresa Bair, Attorney-in-fact for Troy E. Wilson	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kura Oncology (KURA) report for its CEO?

Kura Oncology reported that President and CEO Troy Edward Wilson exercised stock options for 6,103 shares of common stock at $6.15 per share. This was an option exercise, not an open-market purchase or sale, and the option was fully vested.

How many Kura Oncology (KURA) shares does the CEO hold directly after this Form 4?

After the reported option exercise, Troy Edward Wilson directly holds 435,456 shares of Kura Oncology common stock. This figure reflects his direct ownership only and excludes additional shares held indirectly through related trusts listed in the same filing.

Were the Kura Oncology CEO’s options fully vested at the time of exercise?

Yes. A footnote explains that the stock option exercised by Troy Edward Wilson was fully vested. The transaction represents the exercise of 6,103 options into common shares at a strike price of $6.15 per share on March 23, 2026.

Does the Kura Oncology (KURA) Form 4 show any open-market stock sales by the CEO?

No open-market sales are reported in this Form 4. The filing shows an option exercise converting 6,103 options into common stock, along with updated direct and indirect share holdings, but no transactions coded as sales or dispositions.

What indirect Kura Oncology (KURA) holdings are associated with the CEO in this filing?

The Form 4 lists 279,194 shares of Kura Oncology common stock held indirectly by One Fish Two Fish Revocable Trust and 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust, indicating additional ownership through these related entities.

What does the exercise price on the Kura Oncology CEO’s options indicate?

The exercise price of $6.15 per share is the fixed price at which Troy Edward Wilson could convert his stock options into common shares. Exercising 6,103 options at this price increased his direct share ownership without involving an open-market purchase.